ACE inhibitor use was associated with reduced all cause mortality in idiopathic pulmonary fibrosis in a matched real world ...

Medically reviewed by Christopher Lee, MD Key Takeaways ACE inhibitors are used to treat high blood pressure and ...

In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.

Insilico Medicine has received investigational new drug clearance from the US Food and Drug Administration for ISM8969, an oral, brain-penetrant inhibitor of the NOD-like receptor family pyrin ...

CalciMedica had been evaluating the therapy, called Auxora, in the Kourage trial of patients with stage 2 or 3 AKI with ...

Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns overshadowing the drug class. The biopharma, which markets Novartis-partnered ...

The firm will conduct a Phase I trial of its KRAS G12D inhibitor in solid tumors and a Phase II trial of its G12C inhibitor plus an ERK1/2 inhibitor in NSCLC.

Real-world EHR data suggest ACE inhibitor use is independently associated with lower all-cause mortality in idiopathic pulmonary fibrosis, while no similar survival association was observed in COPD.